We're leading the way in IP strategy

Kene Gallois, the head of Daniel Legal & IP Strategy’s Chemical and Life Sciences Group, was named to the latest edition of Intellectual Asset Management magazine’s IAM Strategy 300: The World’s Leading IP Strategists.

Honored for the first time by this prestigious annual guide, Gallois joins other influential leaders in the IP space who have established track records of developing and implementing world-class IP value creation programs. To identify these leaders, IAM spoke with a wide range of senior corporate IP managers and third-party IP service providers. Only those individuals nominated multiple times by different parties as outstanding IP strategists are listed in the IAM Strategy 300.

Kene Gallois joined Daniel Legal & IP Strategy in 2015, where she provides intellectual property strategy and counseling that helps life sciences and biotech companies build their patent portfolios, protect commercial products and processes, maximize returns and extend patent lifecycles, and protect key assets around the world. With more than 10 years of experience, Gallois has a broad range of technical expertise in fields that are key to the life sciences sector, including biochemistry, biomedical engineering, biosimilars, biotechnology, chemistry, cellular and molecular biology, systems biology, medical devices, pharmaceuticals and drug discovery.

“It is an honor to be recognized as a top IP professional and an exciting time to be at Daniel Legal & IP Strategy,” said Gallois. “Our team provides a one-stop source of highly customized, flexible service options that covers the entire product life cycle, from research and development and testing, to clinical trials and distribution. From small, development-stage start-ups to some of the largest and well-known pharmaceutical and biotechnology companies in the world, we take pride in helping clients find creative and strategic paths that foster growth and minimize risk.”